MPN patients carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2 (138), thus have a lower risk of thrombosis and have longer overall survival than those with a JAK2 mutation (130). Here, CALR is linked to myeloproliferative neoplasm.